Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Sarcoma, Ewing × thymoglobulin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myelodysplastic Syndromes 9 Leukemia, Myeloid, Acute 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Leukemia 4 Multiple Myeloma 3 Lymphoma 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Hematologic Neoplasms 3 Primary Myelofibrosis 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myelomonocytic, Juvenile 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Hodgkin Disease 2 Waldenstrom Macroglobulinemia 1 Sarcoma, Ewing 1 Rhabdoid Tumor 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Philadelphia Chromosome 1 Pathologic Complete Response 1 Neuroectodermal Tumors, Primitive 1 Neuroblastoma 1 Myeloid Diseases 1 Myasthenia Gravis 1 Medulloblastoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Leukemia, Prolymphocytic, T-Cell 1 Leukemia, Myeloid 1 Leukemia, Lymphoid 1 Histiocytosis, Langerhans-Cell 1

Interventions

Cyclophosphamide 6 Topotecan 5 Melphalan 5 Busulfan 5 Temozolomide 4 Irinotecan 4 Granulocyte Colony-Stimulating Factor 4 Filgrastim 4 liposomal doxorubicin 3 fludarabine phosphate 3 fludarabine 3 cabozantinib 3 regorafenib 2 pegfilgrastim 2 Vincristine 2 Sirolimus 2 Bone Marrow Transplantation 2 trioctyl phosphine oxide 1 thymoglobulin 1 talazoparib 1 selinexor 1 seclidemstat 1 racotumomab 1 poly ICLC 1 pembrolizumab 1 pegylated granulocyte colony-stimulating factor 1 olaparib 1 niraparib 1 lexatumumab 1 ixazomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02472392 2017-05-09

Ewing/Allo

University of Louisville

Phase 1 Completed

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡